Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co., Inc.

http://www.merck.com

Latest From Merck & Co., Inc.

Trials In Focus: Diverse Enrollment Lagging In Oncology, IQVIA Finds

Also, CRO Syneos Health appointed an executive to its newly created DE&I position, while Alterity started a new Phase II study in multiple system atrophy, Antabio dosed the first patients in its Phase I study of an antibiotic for hospital infections, and Structure Therapeutics started a Phase IIa trial of its GLP-1 agonist in obesity and diabetes, with plans for a Phase IIb trial in 2024.

Clinical Trials Diversity & Inclusion

Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage

Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.

ASCO Clinical Trials

ASCO Preview: Five Top Late-Breakers To Watch For

AstraZeneca plans to unveil multiple major data packages, while Servier reveals much-anticipated results in glioma, and ImmunoGen and Novartis will present key pivotal data in women’s cancers.

ASCO Cancer

Lilly Unlucky? Lilly Leads Big Pharma In US FDA Complete Response Letters

Clinical concerns outweigh quality issues in big pharma CRLs, a Pink Sheet analysis finds, making mirikizumab  the fourth new product candidate sponsored by Lilly to receive a CRL since 2021 – even more of an outlier: it was turned back by FDA because of manufacturing concerns.

US FDA Performance Tracker Complete Response Letters
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abmaxis
    • Acacia Biosciences
    • Acceleron Pharma Inc.
    • Afferent Pharmaceuticals
    • ArQule, Inc.
    • Avecia Biologics Limited
    • Banyu Pharmaceutical Co., Ltd.
    • Calporta Therapeutics
    • cCAM Biotherapeutics Ltd.
    • Cubist Pharmaceuticals, Inc. (Adolor Corporation (ADLR)
    • Calixa Therapeutics, Inc.
    • Optimer Pharmaceuticals, Inc.
    • Trius Therapeutics, Inc.)
    • Idenix Pharmaceuticals, Inc.
    • Immune Design Corporation
    • Inspire Pharmaceuticals, Inc.
    • IOmet Pharma
    • iOnctura SA
    • Integrated Therapeutics Group
    • Merck Sharp & Dohme (MSD) Pharmaceuticals Pvt. Ltd.
    • MSD
    • MSD K.K. (Japan)
    • Nobilon International BV
    • Novacardia
    • OncoEthix SA
    • OncoImmune, Inc.
    • Organon BioSciences
    • Peloton Therapeutics, Inc.
    • Pandion Therapeutics, Inc.
    • Rigontec GmbH
    • Schering-Plough Corporation
    • SmartCells, Inc.
    • Tilos Therapeutics, Inc.
    • Vallee S.A.
    • Viralytics Limited (ASX:VLA)
    • Themis Biosciences GmbH
UsernamePublicRestriction

Register